SCHEMBL16985332

SCHEMBL16985332

CCOC(=O)C(C)(C)n1cc(C)cn1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP4F2 P78329 1/20 0.45
CYP4A11 Q02928 1/20 0.45
FGFR3 P22607 1/20 0.37
KDR P35968 1/20 0.37
CYP3A4 P08684 2/20 0.36
TSHR P16473 2/20 0.36
ABCB11 O95342 1/20 0.36
CYP1A2 P05177 1/20 0.36
HTR2A P28223 1/20 0.36
PMP22 Q01453 1/20 0.36
PPARA Q07869 1/20 0.36
CNR2 P34972 2/20 0.36
MAPK1 P28482 1/20 0.36
HSD17B10 Q99714 1/20 0.36
ALDH1A1 P00352 3/20 0.35
PIN1 Q13526 1/20 0.35
RAB9A P51151 1/20 0.35
CYP2C19 P33261 1/20 0.34
TP53 P04637 1/20 0.34
ALOX15 P16050 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4076690 0.84 CYP4F2 (0.43) CYP4F2CYP4A11FGFR3KDRCYP3A4
SCHEMBL14149259 0.84 CYP4F2 (0.43) CYP4F2CYP4A11FGFR3KDRCYP3A4
SCHEMBL29427420 0.84 ABCB11 (0.44) CYP4F2CYP4A11FGFR3KDRCYP3A4
SCHEMBL16423620 0.84 CYP4F2 (0.43) CYP4F2CYP4A11FGFR3KDRCYP3A4
SCHEMBL13412138 0.84 CYP4F2 (0.43) CYP4F2CYP4A11FGFR3KDRCYP3A4
SCHEMBL13390165 0.83 HCRTR1 (0.38) CNR2HSD17B10ALDH1A1RAB9ACYP2C19
SCHEMBL24627322 0.81 CYP4F2 (0.41) CYP4F2CYP4A11FGFR3KDRCYP3A4
SCHEMBL21086263 0.80 CYP4F2 (0.30) CYP4F2CYP4A11
SCHEMBL29427398 0.80 CYP4F2 (0.31) CYP4F2CYP4A11CYP3A4CYP2C19KMT2A
SCHEMBL29427376 0.80 CYP4F2 (0.31) CYP4F2CYP4A11CYP3A4CYP2C19KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260132143-A1 HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF AMGEN INC. (US) 2026-05-14 US disclosed
EP-4598917-A1 HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF Amgen Inc. (US) 2025-08-13 EP disclosed
EP-4598915-A2 TETHERED HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF Amgen Inc. (US) 2025-08-13 EP disclosed
WO-2024076674-A1 HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF AMGEN INC. (US) 2024-04-11 WO disclosed
WO-2024076674-A1 HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF AMGEN INC. (US) 2024-04-11 WO disclosed
WO-2024076670-A2 TETHERED HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF AMGEN INC. (US) 2024-04-11 WO disclosed
WO-2022064453-A1 NEMATOCIDAL COMPOUNDS AND USE THEREOF PI INDUSTRIES LTD. (IN) 2022-03-31 WO disclosed
WO-2015113452-A1 COMPOUNDS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2015-08-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260132143-A1 HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF KRAS, NRAS, HRAS CYP4F2 3877/4885CYP4A11 2919/4885FGFR3 973/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.